Introducing G4X

A New Era of Multiomic Discovery


High-Throughput In Situ Spatial Sequencing

An ultra high-throughput, high-resolution spatial sequencing platform, enabling rapid and scalable multiomic research.​


Two Technologies.

One Singular Platform.

G4X combines the power of in-situ spatial multiomics with the capabilities of the world’s most powerful benchtop sequencing platform.

Next-Gen Sequencing


4 Flow Cells, 16 Lanes


Daily Sequencing


480 Gb and 1.6 B reads/day

Spatial Sequencing


RNA, Protein, H&E


3-Day Sample-to-Discovery


20x Samples/Week


The World's Most Powerful Benchtop Sequencer

The G4 is an innovative benchtop sequencer with novel, high-performance chemistry and advanced engineering, optimized to deliver unmatched power, speed, and versatility.

Innovation with Intention

Intentionally designed to alleviate challenges faced by researchers in the lab today, the G4 Sequencing Platform features advanced engineering and novel chemistry to deliver faster results, with more operational flexibility. 

Watch Video

Play Video

A Singular Focus

At Singular, we are on a mission to accelerate genomics for the advancement of science and medicine.

  • We are forward-thinking and driven by impactful innovation.
    About Us
  • We are purposeful and collaborative in our approach. We are advancing genomics, together.
    Join Us
A Singular Focus
Product in Development.  For Research Use Only.

Drew Spaventa

Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.

Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.

Max Reads Application Note